Related Experiment Videos
Activity of plafibride on erythrocyte deformability
Abstract:
N-2-(p-Chlorophenoxy)-isobutyryl-N'-morpholinomethylurea (plafibride, Idonor, Perifunal, Plafibrinol) is an acid derivative of morpholinomethylurea and clofibric acid. In these studies the effects of plafibride on haemorheological properties have been observed. The studies have been carried out in different animal species (rat, rabbit and dog), and in human volunteers. Under these circumstances, plafibride has shown itself to be highly active in all the animal species and in humans, as well as with the two laboratory methods used for determination of erythrocyte deformability, these being Teitel's method, which evaluates the deformative capacity of erythrocytes when forming compact groups, and the method of Schmid-Schoenbein in which the deformability of individual erythrocytes is measured by passage through fine capillaries. In trials in volunteers, the increase in erythrocyte deformability is notable even 5 days after the last administration. In addition to its microhaemorheological activity, plafibride has been shown to have effects on platelet aggregation and hyperlipaemia.
Insights
Plafibride significantly improves erythrocyte deformability in animals and humans, enhancing blood flow. This drug also positively impacts platelet aggregation and hyperlipaemia, suggesting broad cardiovascular benefits.
Area of Science:
- Pharmacology
- Hematology
- Cardiovascular Research
Background:
- Plafibride is an acid derivative of morpholinomethylurea and clofibric acid.
- Haemorheological properties are crucial for cardiovascular health.
- Understanding drug effects on blood rheology is vital for therapeutic development.
Purpose of the Study:
- To investigate the effects of plafibride on haemorheological properties.
- To evaluate erythrocyte deformability using established laboratory methods.
- To assess the impact of plafibride on platelet aggregation and hyperlipaemia.
Main Methods:
- Studies conducted in multiple animal species (rat, rabbit, dog) and human volunteers.
- Erythrocyte deformability assessed using Teitel's method and Schmid-Schoenbein's method.
- Observations included effects on platelet aggregation and hyperlipaemia.
Main Results:
- Plafibride demonstrated high activity in improving erythrocyte deformability across all tested species and humans.
- Significant increases in erythrocyte deformability were observed in volunteers up to 5 days post-administration.
- Plafibride also exhibited positive effects on platelet aggregation and reduction of hyperlipaemia.
Conclusions:
- Plafibride possesses significant microhaemorheological activity, enhancing erythrocyte deformability.
- The compound shows potential for managing conditions related to impaired blood flow and hyperlipaemia.
- Further research into plafibride's therapeutic applications in cardiovascular diseases is warranted.